<DOC>
	<DOCNO>NCT00042341</DOCNO>
	<brief_summary>Clofarabine ( injection ) approve Food Drug Administration ( FDA ) treatment pediatric patient 1 21 year old relapse acute lymphoblastic leukemia ( ALL ) least 2 prior treatment regimen . The purpose study determine whether Clofarabine safe effective treatment Acute Lymphoblastic Leukemia ( ALL . )</brief_summary>
	<brief_title>Phase II Study Clofarabine Pediatric Acute Lymphoblastic Leukemia ( ALL )</brief_title>
	<detailed_description>This non-randomized , open label , Phase II study Clofarabine pediatric patient refractory relapse acute lymphoblastic leukemia ( ALL ) . Eligible patient must second subsequent relapse refractory . Forty eligible patient enrol Fleming 2-stage sequential study design order well ass efficacy safety clofarabine patient population .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Have diagnosis ALL accord FAB classification great equal 25 % blast bone marrow . Be le equal 21 year old time initial diagnosis . Not eligible therapy higher curative potential , must second subsequent relapse and/or refractory . Where alternative therapy show prolong survival analogous population , offer patient prior discuss study . Have Karnofsky Performance Status ( KPS ) &gt; 70 . Provide sign , write informed consent parent guardian assent patient great equal 7 year old accord local IRB institutional requirement . Be able comply study procedure followup examination . Have adequate organ function indicate follow laboratory value , obtain within 2 week prior registration : Serum bilirubin less equal 1.5 x ULN ; AST ALT less equal 5 x ULN ; Serum Creatinine le 2 x ULN age . ULN= Institutional Upper Limit Normal Received previous treatment Clofarabine . Have recent ( &lt; 30 day ) history fungal serious bacterial infection receive therapeutic antibiotic . Are pregnant lactating . Male female patient fertile must agree use effective mean birth control ( i.e. , latex condom , diaphragm , cervical cap , etc ) avoid pregnancy . Have psychiatric disorder would interfere consent , study participation , follow . Are receive chemotherapy . Patients must previous therapy least 2 week ( exception intrathecal therapy , allow 24hrs prior 1st study drug ) must recover acute toxicity previous therapy prior enrollment . Treatment may start early , follow consultation ILEX Medical Monitor , evidence disease relapse prior time . Have severe concurrent disease , history serious organ dysfunction disease involve heart , kidney , liver pancreas . Have symptomatic CNS involvement . Febrile neutropenia time study entry . Have receive hematologic stem cell transplant ( HSCT ) within previous 3 month active GVHD ( great equal Grade 2 ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>CLO212</keyword>
	<keyword>clolar</keyword>
	<keyword>pediatric ALL</keyword>
	<keyword>Leukemia , Lymphoblastic , Acute - pediatric</keyword>
</DOC>